CELC
NASDAQ HealthcareCelcuity Inc. - Common Stock
Biotechnology
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
๐ Market Data
| Price | $92.44 |
|---|---|
| Volume | 720,927 |
| Market Cap | 4.52B |
| Beta | 0.200 |
| RSI (14-Day) | 64.8 |
| 200-Day MA | $105.23 |
| 50-Day MA | $93.58 |
| 52-Week High | $151.02 |
| 52-Week Low | $44.42 |
| Forward P/E | -560.24 |
| Price / Book | -354.18 |
๐ฏ Investment Strategy Scores
CELC scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (70/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (10/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find CELC in your text
Paste any article, transcript, or post โ the tool will extract CELC and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.